Corporate Profile
We are a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small-molecule product candidates that target cancer signaling pathways, and we intend to pair them with molecular or cellular diagnostics to identify those patients most likely to respond to treatment. We intend to advance our product candidates through a combination of internal development and strategic partnerships and maintain significant development and commercial rights.
Press Releases
Events
-
09-26-2023 at 11:05 AM EDT
-
08-03-2023 at 4:30 PM EDT
-
06-12-2023 at 8:00 AM EDT